Also listed on Horizon Pharma Rheumatology LLC, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Sep 10, 2027 · High confidence
20-year base term ended Apr 12, 2026
Held by Horizon Therapeutics USA, Inc.
Filed Aug 14, 2009 as application 11/918,292 · Granted Jan 3, 2017
Base term plus 516 days of patent term adjustment (USPTO delay)
Today
2006
2027
Clock starts
Apr 12, 2006
Apr 12, 2006
Term ends
Sep 10, 2027
Sep 10, 2027
Granted
Jan 3, 2017
Jan 3, 2017
base term
patent term adjustment
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
516
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 516 days past its 20-year base term on prosecution delay. 2 of 2 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 12, 2006, when application PCT/US2006/013751, the earliest non-provisional in its chain, was filed (this one was filed Aug 14, 2009) | Apr 12, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +516 days, USPTO patent term adjustment record | Sep 10, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 10, 2027 | High confidence |
This family
| US 9,534,013 | this patent Sep 2027 | Sep 2027 |
| Application 15/356,046 | Abandoned not computed | not computed |
| Application 16/455,073 | Abandoned not computed | not computed |
| Application 17/325,555 | Abandoned not computed | not computed |
| Application 18/376,684 | Abandoned not computed | not computed |
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 18, 2008 Reel 20383, frame 946 | Fischer, Meir; Harosh, Eliyahu | Savient Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jun 12, 2012 Reel 28363, frame 40 | Savient Pharmaceuticals, Inc. | Morgan Stanley Senior Funding Inc. | Security Agreement |
| Jul 23, 2013 Reel 30936, frame 72 | Savient Pharmaceuticals, Inc. | U.S. National Bank Association, as Collateral Agent | Corrective Assignment to Correct the Receiving Party Previously Recorded on Reel 028363 Frame 0040. Assignor(S) Hereby Confirms the Security Agreement. |
| Feb 21, 2014 Reel 32319, frame 77 | Crealta Pharmaceuticals LLC | Jefferies Finance LLC, as Collateral Agent | Security Agreement |
| Mar 4, 2014 Reel 32384, frame 285 | Crealta Pharmaceuticals LLC | Fifth Street Finance Corp., as Collateral Agent | Security Agreement |
| Apr 15, 2014 Reel 32675, frame 936 | Savient Pharmaceuticals, Inc.; Savient Pharma Holdings, LLC | Crealta Pharmaceuticals LLC | Assignment of Assignor's Interest |
| Jan 13, 2016 Reel 37483, frame 49 | Fifth Street Finance Corp., as Collateral Agent | Crealta Pharmaceuticals LLC | Release of Security Interest |
| Jan 13, 2016 Reel 37483, frame 148 | Jefferies Finance LLC, as Collateral Agent | Crealta Pharmaceuticals LLC | Release of Security Interest |
| Sep 16, 2016 Reel 40059, frame 7 | Horizon Pharma Rheumatology LLC (Formerly Known as Crealta Pharmaceuticals LLC) | Citibank, N.A., as Collateral Agent | Patent Security Agreement |
| Nov 18, 2016 Reel 40648, frame 361 | Crealta Pharmaceuticals LLC | Horizon Pharma USA Rheumatology LLC | Change of Name |
| Nov 18, 2016 Reel 40648, frame 367 | Horizon Pharma USA Rheumatology LLC | Horizon Pharma Rheumatology LLC | Change of Name |
| Oct 31, 2022 Reel 61805, frame 76 | Horizon Pharma Rheumatology LLC | Horizon Therapeutics USA, Inc. | Assignment of Assignor's Interest |
| Dec 1, 2022 Reel 62073, frame 930 | Horizon Pharma Rheumatology LLC | Horizon Therapeutics USA, Inc. | Corrective Assignment to Correct the Name of the Assignee Previously Recorded on Reel 061805 Frame 0076. Assignor(S) Hereby Confirms the Assignment. |
| Jun 16, 2023 Reel 64009, frame 261 | Savient Pharmaceuticals, Inc.; Savient Pharma Holdings, Inc. | Crealta Pharmaceuticals LLC | Corrective Assignment to Correct the Seller's Name and Execution Date Previously Recorded on Reel 032675 Frame 0936. Assignor(S) Hereby Confirms the Seller's Name Should Read Savient Pharma Holdings, Inc. and the Execution Date for Both Parties Should Read 01/09/2014. |
| Oct 6, 2023 Reel 65178, frame 965 | Citibank, N.a. | Horizon Therapeutics USA, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Sep 2027
Term ends Sep 10, 2027. No further fees fall due before then
Note
The 516 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
46
later US patents cite this one
That is top 10% of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.